Cannabidiol-2′,6′-Dimethyl Ether, a Cannabidiol Derivative, Is a Highly Potent and Selective 15-Lipoxygenase Inhibitor

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Drug Metabolism And Disposition

• Publication date

  2009-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/dmd.109.026930PMID 19406952
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interaction of Cytochrome P450 3A4 and UDP-Glucuronosyltransferase 2B7: Evidence for Protein-Protein Association and Possible Involvement of CYP3A4 J-Helix in the Interaction

  2009cited by this paper
• Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?

  2008cited by this paper
• Cannabidiolic Acid as a Selective Cyclooxygenase-2 Inhibitory Component in Cannabis

  2008cited by this paper
• Generation of reactive oxygen species during mouse hepatic microsomal metabolism of cannabidiol and cannabidiol hydroxy-quinone.

  2008cited by this paper
• Inhibition of IGF-1R and lipoxygenase by nordihydroguaiaretic acid (NDGA) analogs.

  2007cited by this paper
• Cannabinoid receptors in atherosclerosis

  2006cited by this paper
• INHIBITION OF UDP-GLUCURONOSYLTRANSFERASE 2B7-CATALYZED MORPHINE GLUCURONIDATION BY KETOCONAZOLE: DUAL MECHANISMS INVOLVING A NOVEL NONCOMPETITIVE MODE

  2006cited by this paper
• Marijuana extracts possess the effects like the endocrine disrupting chemicals.

  2005cited by this paper
• Modulation of UDP-Glucuronosyltransferase Function by Cytochrome P450: Evidence for the Alteration of UGT2B7-Catalyzed Glucuronidation of Morphine by CYP3A4

  2005cited by this paper
• Modulation of UDP-glucuronosyltransferase 2B7 function by cytochrome P450s in vitro: differential effects of CYP1A2, CYP2C9 and CYP3A4.

  2005cited by this paper
• Functional protein-protein interaction of drug metabolizing enzymes.

  2005cited by this paper
• 6"-Azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist.

  2004cited by this paper
• A Novel Pathway Involving Progesterone Receptor, 12/15-Lipoxygenase-derived Eicosanoids, and Peroxisome Proliferator-activated Receptor γ Regulates Implantation in Mice*

  2004cited by this paper
• Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?

  2004cited by this paper
• International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels

  2003cited by this paper
• Lipoxygenase interactions with natural flavonoid, quercetin, reveal a complex with protocatechuic acid in its X‐ray structure at 2.1 Å resolution

  2003cited by this paper
• Inhibition of 15-lipoxygenases by flavonoids: structure-activity relations and mode of action.

  2003influential reference
• Structure−Activity Relationship Studies of Nordihydroguaiaretic Acid Inhibitors toward Soybean, 12-Human, and 15-Human Lipoxygenase

  2002influential reference
• International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors

  2002cited by this paper
• Lipoxygenase - a versatile biocatalyst for biotransformation of endobiotics and xenobiotics

  2001cited by this paper
• The diversity of the lipoxygenase family

  1999cited by this paper
• Lipoxygenases: Occurrence, Functions, Catalysis, and Acquisition of Substrate*

  1999cited by this paper
• Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice.

  1999cited by this paper
• Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator.

  1998cited by this paper
• Inhibitors of Arachidonate Lipoxygenase from Defatted Perilla Seed

  1998cited by this paper
• In vivo action of 15-lipoxygenase in early stages of human atherogenesis.

  1997cited by this paper
• The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice.

  1996cited by this paper
• Regiochemistry of cytochrome P450 isozymes.

  1994cited by this paper
• Cellular oxidative modification of low density lipoprotein does not require lipoxygenases.

  1992cited by this paper
• Inhibitory effect of cannabidiol hydroxy-quinone, an oxidative product of cannabidiol, on the hepatic microsomal drug-metabolizing enzymes of mice.

  1991cited by this paper
• Cannabielsoin as a new metabolite of cannabidiol in mammals.

  1991cited by this paper
• In vivo and in vitro metabolism of cannabidiol monomethyl ether and cannabidiol dimethyl ether in the guinea pig: on the formation mechanism of cannabielsoin-type metabolite from cannabidiol.

  1990influential reference
• Actions of cannabis constituents on enzymes of arachidonate metabolism: anti-inflammatory potential.

  1987cited by this paper
• Cannabinoid pharmacology.

  1986cited by this paper
• Pharmacological profile of AA-861, a 5-lipoxygenase inhibitor.

  1983cited by this paper
• In vitro inhibition of the biosynthesis of slow reacting substance of anaphylaxis (SRS-A) and lipoxygenase activity by quercetin.

  1983cited by this paper
• Constituents of Cannabis sativa L. XVII. A review of the natural constituents.

  1980cited by this paper
• Marihuana chemistry.

  1970cited by this paper
• Hashish--13. On the nature of the Beam test.

  1968cited by this paper
• Forensic chemical study on marihuana. I. A detection method of the principal constituents by thin-layer and gas chromatographies.

  1968cited by this paper

• Therapeutic potential of cannabidiol supplementation in mitigating lipid precursors of inflammation in hepatic steatosis progression.

  2026cites this paper
• Single-Cell Analysis, Spatial Transcriptomics and Molecular Docking Unveil Potential Therapeutic Targets for Carotid Atherosclerosis

  2025cites this paper
• Molecular targets of cannabinoids and their derivatives in epilepsy – a review with focus on CBD

  2025cites this paper
• Cannabidiol and its application in the treatment of oral diseases: therapeutic potentials, routes of administration and prospects.

  2024cites this paper
• Cannabidiol for Oral Health: A New Promising Therapeutical Tool in Dentistry

  2023cites this paper
• Effects of cannabidiol on anandamide levels in individuals with cannabis use disorder: findings from a randomised clinical trial for the treatment of cannabis use disorder

  2023cites this paper
• How do phytocannabinoids affect cardiovascular health? An update on the most common cardiovascular diseases

  2023cites this paper
• Cannabidiol acts as molecular switch in innate immune cells to promote the biosynthesis of inflammation-resolving lipid mediators.

  2023cites this paper
• An overview on synthetic and biological activities of cannabidiol (CBD) and its derivatives.

  2023cites this paper
• Can cannabidiol have an analgesic effect?

  2023cites this paper
• Δ^9-Tetrahydrocannabinol stimulation of estrogen receptor-positive MCF-7 breast cancer cell migration: Interfering interaction with the estrogenic milieu

  2022cites this paper
• Obesity as a Condition Determined by Food Addiction: Should Brain Endocannabinoid System Alterations Be the Cause and Its Modulation the Solution?

  2021cites this paper
• Cannabinoids and myocardial ischemia: Novel insights, updated mechanisms, and implications for myocardial infarction.

  2021cites this paper
• Topical cannabis‐based medicines – A novel adjuvant treatment for venous leg ulcers: An open‐label trial

  2021cites this paper
• Pharmacological Properties of the Plant-Derived Natural products Cannabinoids and Implications for Cardiovascular Health.

  2021cites this paper
• Understanding the complex pharmacology of cannabidiol: mounting evidence suggests a common binding site with cholesterol.

  2021cites this paper
• Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action

  2020cites this paper
• Topical cannabis‐based medicines – A novel paradigm and treatment for non‐uremic calciphylaxis leg ulcers: An open label trial

  2020cites this paper
• O-Methyl Phytocannabinoids: Semi-synthesis, Analysis in Cannabis Flowerheads, and Biological Activity

  2019cites this paper
• Cannabinoid interventions for PTSD: Where to next?

  2019cites this paper
• Using Cannabis to Treat Cancer-Related Pain.

  2019cites this paper
• Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science

  2018cites this paper
• The importance of 15-lipoxygenase inhibitors in cancer treatment

  2018cites this paper
• Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort

  2018cites this paper
• An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol

  2017cites this paper
• Computer modeling in predicting the bioactivity of human 5-lipoxygenase inhibitors

  2017cites this paper
• 15-Lipoxygenase inhibitors: a patent review

  2016cites this paper
• Bongkrekic Acid as a Warburg Effect Modulator in Long-term Estradiol-deprived MCF-7 Breast Cancer Cells.

  2016cites this paper
• Cannabidiol-2',6'-dimethyl ether stimulates body weight gain in apolipoprotein E-deficient BALB/c. KOR/Stm Slc-Apoe(shl) mice.

  2015cites this paper
• Bongkrekic acid as a selective activator of the peroxisome proliferator-activated receptor γ (PPARγ) isoform.

  2015cites this paper
• Molecular Targets of Cannabidiol in Neurological Disorders

  2015cites this paper
• The Effects of Cannabidiol on the Electrical and Contractile Properties of Cardio myocytes

  2014cites this paper
• Down-regulation of cyclooxygenase-2 (COX-2) by cannabidiolic acid in human breast cancer cells.

  2014cites this paper
• Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol.

  2014cites this paper
• Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

  2013cites this paper
• [Medicinal chemistry and pharmacology focused on cannabidiol, a major component of the fiber-type cannabis].

  2013cites this paper
• Structural requirements for potent direct inhibition of human cytochrome P450 1A1 by cannabidiol: role of pentylresorcinol moiety.

  2013cites this paper
• Cannabinoids and Atherosclerotic Coronary Heart Disease

  2012cites this paper
• Δ9-tetrahydrocannabinol and its major metabolite Δ9-tetrahydrocannabinol-11-oic acid as 15-lipoxygenase inhibitors.

  2011cites this paper
• Cannabidiol-2',6'-dimethyl ether as an effective protector of 15-lipoxygenase-mediated low-density lipoprotein oxidation in vitro.

  2011cites this paper
• Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress.

  2011cites this paper
• (--)-Xanthatin selectively induces GADD45γ and stimulates caspase-independent cell death in human breast cancer MDA-MB-231 cells.

  2011cites this paper
• The Journal of Toxicological Sciences

  2009cites this paper
• Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb.

  2009cites this paper